Trials / Terminated
TerminatedNCT00664573
104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 339 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Baminercept alfa (BG9924) | dosage administered as per Biogen-Idec protocol |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-04-23
- Last updated
- 2016-01-21
Locations
8 sites across 8 countries: Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT00664573. Inclusion in this directory is not an endorsement.